Immunohistochemical expression of SOX2 in oral normal epithelial, dysplasia and squamous cell carcinoma
AbstractObjective: Oral squamous cell carcinoma (SCC) is an aggressive neoplasm with serious morbidityand mortality, which typically spreads through local invasive growth. A key approach to this tumor would be to detect potentially malignant lesions at their early stages. The transcription factor, Sex determining region Y-box 2 (SOX2) is an essential regulator of pluripotent stem cells and promotes developmentand maintenance of squamous epithelia. Materials and Methods: We retrospectively reviewed the charts of 24 samples of SCC, oral epithelial dysplasia and control group, then immunohistochemical staining was performed to detect SOX2 expression. Results: Comparisons between SCC and oral epithelial dysplasia group did not reveal any significant difference (p=0.496); also values of control and oral epithelial dysplasia group were statically different (p<0.001). Similarly, a significant difference was observed between the values of SCC and controls’ (p<0.001). Conclusion: In conclusion, SOX2 overexpression is seen in oral dysplasia and SCC and their detection in early stages could be crucial for early tumor identification. Keywords: Oral squamous cell carcinoma, Oral epithelial dysplasia, SOX2.
Brusevold IJ, Tveteraas IH, Aasrum M, et al. Role of LPAR3, PKC and EGFR in LPA-induced cell migration in oral squamous carcinoma cells. BMC Cancer. 2014; 13: 432.
Naher L, Kiyoshima T, Kobayashi I, et al. STAT3 signal transduction through interleukin-22 in oral squamous cell carcinoma. Int J Oncol. 2012; 41: 1577–1586.
Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011; 61: 69–90.
Kokalj Vokač N, Cizmarević B, Zagorac A, et al. evaluation of SOX2 and hTERC gene amplifications as screening markers in oral and oropharyngeal squamous cell carcinomas. Mol Cytogenet. 2014; 7: 5.
Chen IH, Liao CT, Wang HM, et al. Using SCC Antigen and CRP Levels as Prognostic Biomarkers in Recurrent Oral Cavity Squamous Cell Carcinoma. PLoS One. 2014; 9:e103265.
Lin WH, Chen IH, Wei FC, Huang JJ, et al. Clinical significance of preoperative squamous cell carcinoma antigen in oral-cavity squamous cell carcinoma. Laryngoscope. 2011; 121: 971–977.
Kim Y, Shintani S, Kohno Y, et al. Cyclin G2 Dysregulation in Human Oral Cancer. Cancer Res. 2004; 64: 8980–8986.
Velcheti V, Schalper K, Yao X, et al. High SOX2 levels predict better outcome in non-smallcell lung carcinomas. PLoS One. 2013; 8: e61427.
Graham V, Khudyakov J, Ellis P, Pevny L .SOX2 functions to maintain neural progenitor identity. Neuron. 2003; 39: 749–765.
Watanabe M, Ohnishi Y, Wato M, et al. SOX4 expression is closely associated with differentiation and lymph node metastasis in oral squamous cell carcinoma. Med mol morphol. 2014; 47: 150-5.
Baillie R, Tan ST, Itinteang T. Cancer Stem Cells in Oral Cavity Squamous Cell Carcinoma: A Review. Front Oncol. 2017;7.
Yoshihama R, Yamaguchi K, Imajyo I, et al. Expression levels of SOX2, KLF4 and brachyury transcription factors are associated with metastasis and poor prognosis in oral squamous cell carcinoma. Oncol lette. 2016; 11: 1435-46.
Watanabe H, Ma Q, Peng S, et al. SOX2 and p63 colocalize at genetic lociin squamous cell carcinomas. J Clin Invest. 2014; 124: 1636–1645.
Ge N, Lin HX, Xiao XS, et al. Prognostic significance of Oct4 and Sox2expression in hypopharyngeal squamous cell carcinoma. J Transl Med. 2010; 8 :94.
Schröck A, Göke F, Wagner P, et al. Sex Determining Region Y-Box 2 (SOX2) Amplification Is an Independent Indicator of Disease Recurrence in Sinonasal Cancer. PLOS ONE. 2013; 8: e59201.
Toschi L, Finocchiaro G, Nguyen TT, et al. Increased SOX2 Gene Copy Number Is Associated withFGFR1 and PIK3CA Gene Gain in Non-Small Cell Lung Cancer and Predicts Improved Survival in Early Stage Disease. PLOS ONE. 2014; 9: e95303.
Fu TY, Hsieh IC, Cheng JT, et al. Association of OCT4, SOX2, and NANOG expression with oral squamous cell carcinoma progression. J Oral Pathol Med. 2016; 45:89-95.
Brcic L, Sherer CK, Shuai Y, et al. Morphologic and Clinicopathologic Features of Lung Squamous Cell Carcinomas Expressing Sox2. Am J Clin Pathol. 2012; 138: 712-718.
Hussenet T, Dali S, Exinger J, et al. SOX2 Is an Oncogene Activated by Recurrent 3q26.3 Amplifications in Human Lung Squamous Cell Carcinomas. PLOS ONE. 2010; 5: e8960.
Nagaraja V, Eslick GD. Forthcoming prognostic markers for esophageal cancer: asystematic review and meta-analysis. J Gastrointest Oncol. 2014; 5: 67-76.
Bass AJ, Watanabe H, Mermel CH, et al. SOX2 Is an Amplified Lineage Survival Oncogene in Lung and Esophageal Squamous Cell Carcinomas. Nat Genet. 2009; 41: 1238–1242.
He KF, Zhang L, Huang CF, et al. CD163+ tumor-associated macrophages correlated with poor prognosis and cancer stem cells in oral squamous cell carcinoma. Biomed Res Int. 2014: 838632, 2014.
Cha JD, Kim HJ, Cha IH. Genetic alterations in oral squamous cell carcinoma progression detected by combining array-based comparative genomic hybridization and multiplex ligation-dependent probe amplification. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011; 111: 594–607.
Wang Ql, He W, Lu C, et al. Oct3/4 and Sox2 are significantly associated with an unfavorable clinical outcome in human esophageal squamous cell carcinoma. Anticancer Res. 2009; 29: 1233-41.
A signature of author below certifies compliance with the following statements:
Copyright transfer; in signing this Agreement:
1. I hereby warrant that this article is an original work, has not been published before and is not being considered for publication elsewhere in its final form either in printed or electronic form;
2. I hereby warrant that you have obtained permission from the copyright holder to reproduce in the Article (in all media including print and electronic form) material not owned by you, and that you have acknowledged the source;
3. I hereby warrant that this article contains no violation of any existing copyright, moral rights or other third party right or any material of an obscene, indecent, defamatory or otherwise unlawful nature and that to the best of your knowledge this Article does not infringe the rights of others;
4. I hereby warrant that in the case of a multi-authored Article you have obtained, in writing, authorization to enter into this Agreement on their behalf and that all co-authors have read and agreed the terms of this agreement;
5. I warrant that any formula or dosage given is accurate and will not if properly followed injure any person;
6. I have made a significant scientific contribution to the study and I have read the complete manuscript and take responsibility for the content and completeness of the final surmised manuscript;
7. I will indemnify and keep indemnified the Editors, the Journal's Editor against all claims and expenses (including legal costs and expenses) arising from any breach of this warranty and the other warranties on your behalf in this Agreement.
Conflict of interest disclosure
All institutional or corporeal affixations of mine and all funding sources for the study are acknowledged. I certify that I have no commercial association that might represent a conflict of interest in connection with the submitted manuscript.